期刊文献+

炎症因子参与神经病理性疼痛抑郁共病的研究进展 被引量:13

Inflammatory cytokines in comorbidity of neuropathic pain and depression
原文传递
导出
摘要 背景 神经病理性疼痛与抑郁症共病严重影响了患者的生活质量。近年来研究发现,炎症因子在神经病理性疼痛?蛳抑郁共病发病中起重要作用。 目的 综述炎症因子参与神经病理性疼痛-抑郁共病的研究进展,为该病的有效防治提供参考 内容 神经病理性疼痛与感觉系统的功能障碍相关,它包括触诱发痛、痛觉过敏、自发痛等一系列疼痛症状。抑郁症表现为心境低落和厌恶活动。小胶质细胞激活后,释放的炎症因子如TNF-α、IL-6、IL-1β,通过结合5-羟色胺受体、谷氨酸盐受体、γ-氨基丁酸能受体及激活下丘脑-垂体-肾上腺素轴促进神经病理性疼痛和抑郁症的发生。 趋向 炎症因子可能是治疗神经病理性疼痛-抑郁共病的靶标。 Background Comorbidity of neuropathic pain and depression seriously affects life quality. Recent studies have found that cytokines play important roles in the pathogenesis of neuropathic pain-depression comorbidity. Objective To review the effects of inflammatory cytokines on neuropathic pain-depression comorbidity, which will provide clues for effective prevention and treatment of the comorbidity. Content Neuropathic pain is associated with injuries and dysfunctions of somatosensory nervous system, and consists of a series of pain symptoms, including allodynia, pain hypersensitivity, and spontaneous pain, etc. Depression is a state of low mood and aversion to activity. Following activation of microglia, many inflammatory cytokines, such as, TNF-α, IL-1β, and IL-6, elevate and subsequently exacerbate both neuropathic pain and depression by interacting with 5-HT receptors, glutamate receptors, γ-aminobutyric acid receptors, and promoting activation of hypothalamus-pituitary-adrenaline axis. Trend Inflammatory cytokines may be potential targets for the treatment of neuropathic pain-depression comorbidity.
出处 《国际麻醉学与复苏杂志》 CAS 2017年第7期656-659,668,共5页 International Journal of Anesthesiology and Resuscitation
基金 国家自然科学基金(81571083)
关键词 神经病理性疼痛 抑郁症 炎症因子 Neuropathic pain Depression Inflammatory cytokine
  • 相关文献

参考文献2

二级参考文献62

  • 1Kessler RC,Berglund P,Demler O. The epidemiology of major depressive disorder:results from the National Comorbidity Survey Replication (NCS-R)[J].Journal of the American Medical Association,2003,(23):3095-3105.
  • 2Check E. Depression:Comfortably numb[J].Nature,2006,(7112):629-631.
  • 3Berman RM,Cappiello A,Anand A. Antidepressant effects of ketamine in depressed patients[J].Biological Psychiatry,2000,(04):351-354.
  • 4Zarate CA,Singh JB,carlson PJ. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression[J].Archives of General Psychiatry,2006,(08):856-862.
  • 5Ibrahim L,Diazgranados N,Luckenbaugh D. Rapid decrease in depressive symptoms with an N-methyl-D-aspartate antagonist in ECT-resistant major depression[J].Progress in Neuro-Psychopharmacology & Biological Psychiatry,2011,(04):1155-1159.
  • 6Paul R,Schaaff N,Padberg F. Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression:report of two cases[J].World Journal of Biological Psychiatry,2009,(03):241-244.
  • 7Price R,Nock M,Chamey D. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression[J].Biological Psychiatry,2009,(05):522-526.
  • 8Larkin GL,Beautrais AL. Preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department[J].International Journal of Neuropsychopharmacology,2011,(08):1127-1131.
  • 9Irwin SA,Iglewicz A. Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care[J].Journal of Palliative Medicine,2010,(07):903-908.
  • 10Li N,Lee B,Liu RJ. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists[J].Science,2010,(5994):959-964.

共引文献6

同被引文献118

引证文献13

二级引证文献73

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部